These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23328800)

  • 21. Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma.
    Holló G; Kóthy P; Géczy A; Vargha P
    J Glaucoma; 2009; 18(4):288-92. PubMed ID: 19365193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients.
    Schlote T; Tzamalis A; Kynigopoulos M
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):459-62. PubMed ID: 19857108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
    Reardon G; Schwartz GF; Mozaffari E
    Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database.
    De Natale R; Lafuma A; Berdeaux G
    Clin Drug Investig; 2009; 29(2):111-20. PubMed ID: 19133706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma.
    Hahn SR; Kotak S; Tan J; Kim E
    Curr Med Res Opin; 2010 Apr; 26(4):957-63. PubMed ID: 20163296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
    Li N; Chen XM; Zhou Y; Wei ML; Yao X
    Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors.
    Sayner R; Carpenter DM; Blalock SJ; Robin AL; Muir KW; Hartnett ME; Giangiacomo AL; Tudor G; Sleath B
    Clin Ther; 2015 Sep; 37(9):1975-85. PubMed ID: 26164785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database.
    Lafuma A; Berdeaux G
    Curr Med Res Opin; 2007 Dec; 23(12):3009-16. PubMed ID: 17958945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraocular pressure lowering efficacy of travoprost.
    Przydryga JT; Egloff C;
    Eur J Ophthalmol; 2004; 14(5):416-22. PubMed ID: 15506604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%.
    Orengo-Nania S; Landry T; Von Tress M; Silver LH; Weiner A; Davis AA;
    Am J Ophthalmol; 2001 Dec; 132(6):860-8. PubMed ID: 11730649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension.
    Ge J; Sun XH; Wang NL; Zhao JL; Wu LL; Chen XM; Wang ZX; Li B
    Chin Med J (Engl); 2010 Jun; 123(11):1417-21. PubMed ID: 20819599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma.
    Parmaksiz S; Yüksel N; Karabas VL; Ozkan B; Demirci G; Caglar Y
    Eur J Ophthalmol; 2006; 16(1):73-80. PubMed ID: 16496249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension.
    Pfeiffer N;
    Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):1065-71. PubMed ID: 21499770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.
    Holló G; Kóthy P
    Curr Med Res Opin; 2008 Jun; 24(6):1755-61. PubMed ID: 18479590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diurnal and nocturnal effect of travoprost with sofZia on intraocular pressure and ocular perfusion pressure.
    Seibold LK; Kahook MY
    Am J Ophthalmol; 2014 Jan; 157(1):44-49.e1. PubMed ID: 24182742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of a predictive model for nonadherence with once-daily glaucoma medications.
    Chang DS; Friedman DS; Frazier T; Plyler R; Boland MV
    Ophthalmology; 2013 Jul; 120(7):1396-402. PubMed ID: 23541760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.